Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants

Exclusion Criteria

• •1. History or evidence, at Screening or Check-in, of clinically significant disorder, condition, or disease
• •2. History or current signs or symptoms of cardiovascular disease
• •3. History or evidence of clinically significant arrhythmia at Screening, including any clinically significant findings on the ECG taken at Check-in
• •4. History of hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance
• •5. Positive hepatitis B or hepatitis C panel and/or positive human immunodeficiency virus test at Screening
• •6. History of alcoholism or drug/chemical abuse within 1 year prior to Check-in
• •7. Use of tobacco- or nicotine-containing products within 6 months prior to Check-in
• •8. Positive test for illicit drugs, cotinine (tobacco or nicotine use), and/or alcohol use at Screening or Check-in
• •9. Female participants with a positive pregnancy test at Screening or Check-in
• •10. Female participants lactating/breastfeeding or who plans to breastfeed during the study through 90 days after the end of study (EOS) visit
• •11. Donation of blood from 3 months prior to Check-in, plasma from 2 weeks prior to Check-in, or platelets from 6 weeks prior to Check-in
• •12. Unwilling to abide with study restrictions